Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President, CEO Paul McBarron - EVP, Finance & COO Mark Kirschbaum - SVP, CMO Conference Call Participants Ahu Demir - Ladenburg Thalmann Jonathan Aschoff - ROTH MKM Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2023 Results Conference Call and Webcast. [Operator Instructions] Please note, today's call is being reco ...

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Grace Kim - Investor Relations Spiro Rombotis - President and Chief Executive Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Paul McBarron - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann Jeff Jones - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Good a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number 000-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specifi ...

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO Conference Call Participants Ahu Demir - Ladenburg Thalmann Shubhendu Sen Roy - Brookline Capital Markets Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2023 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. After today’s call membe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number 000-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specif ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 00-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 91-1707622 (State or Other Jurisdiction of Incorp ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Irina Koffler - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Ahu Demir - Ladenburg Jeff Jones - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President & Chief Executive Officer Mark Kirschbaum - Senior Vice President & Chief Medical Officer Paul McBarron - Executive Vice President, Finance & Chief Operating Officer Conference Call Participants Ahu Demir - Ladenburg Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceutica ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CYCC The Nasdaq Stock Market LLC Preferred Stock, $0.001 par value CYCCP The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECT ...

Corporate Presentation September 2022 Translating cancer biology into medicines Disclaimer This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forwardlooking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candid ...